Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...